ASLAN Pharmaceuticals announced that it has screened the first patient in its Phase IIb dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis.
[ASLAN Pharmaceuticals]
Sorry, but the selected Zotpress account can't be found.
